Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.91 USD | -2.05% | +6.34% | -5.97% |
07/05 | Bioceres Crop Solutions Corp. Announces Brazil?s Approval of New Generation Bio-Insecticide | CI |
08/02 | Transcript : Bioceres Crop Solutions Corp., Q2 2024 Earnings Call, Feb 08, 2024 |
Valuation
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 191.4 | 218.9 | 567.2 | 565.2 | 839.3 | 811.1 | - | - |
Enterprise Value (EV) 1 | 191.4 | 218.9 | 567.2 | 565.2 | 839.3 | 811.1 | 1,008 | 811.1 |
P/E ratio | - | - | - | -80.6 x | 45 x | 31.7 x | 11.3 x | 7.42 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 1.19 x | 1.26 x | 2.71 x | 1.69 x | 2 x | 1.65 x | 1.36 x | 1.04 x |
EV / Revenue | 1.19 x | 1.26 x | 2.71 x | 1.69 x | 2 x | 1.65 x | 1.36 x | 1.04 x |
EV / EBITDA | - | 4.71 x | 11.7 x | 11 x | 10.3 x | 8.69 x | 6.24 x | - |
EV / FCF | - | - | -39.1 x | -26.9 x | -95.7 x | 13.1 x | 7.42 x | - |
FCF Yield | - | - | -2.56% | -3.71% | -1.05% | 7.61% | 13.5% | - |
Price to Book | - | - | - | - | 2.91 x | 2.26 x | 1.62 x | - |
Nbr of stocks (in thousands) | 36,121 | 36,121 | 40,371 | 41,228 | 62,821 | 62,828 | - | - |
Reference price 2 | 5.300 | 6.060 | 14.05 | 13.71 | 13.36 | 12.91 | 12.91 | 12.91 |
Announcement Date | 13/09/19 | 10/09/20 | 09/09/21 | 08/09/22 | 11/09/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 160.6 | 173.1 | 209.5 | 334.8 | 419.8 | 492.4 | 598.3 | 781.1 |
EBITDA 1 | - | 46.5 | 48.3 | 51.5 | 81.1 | 93.36 | 130 | - |
EBIT 1 | - | 39.15 | 38.33 | 39.93 | 54.1 | 72.29 | 112.3 | 177 |
Operating Margin | - | 22.62% | 18.29% | 11.93% | 12.89% | 14.68% | 18.77% | 22.66% |
Earnings before Tax (EBT) 1 | - | - | - | 13.98 | 18.8 | 46.4 | 98.38 | 168.9 |
Net income 1 | - | - | - | -7.332 | 16.7 | 26.24 | 75.1 | 114.6 |
Net margin | - | - | - | -2.19% | 3.98% | 5.33% | 12.55% | 14.67% |
EPS 2 | - | - | - | -0.1702 | 0.2972 | 0.4067 | 1.147 | 1.740 |
Free Cash Flow 1 | - | - | -14.52 | -20.97 | -8.772 | 61.7 | 109.3 | - |
FCF margin | - | - | -6.93% | -6.26% | -2.09% | 12.53% | 18.27% | - |
FCF Conversion (EBITDA) | - | - | - | - | - | 66.09% | 84.06% | - |
FCF Conversion (Net income) | - | - | - | - | - | 235.16% | 145.54% | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 13/09/19 | 10/09/20 | 09/09/21 | 08/09/22 | 11/09/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: June | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 66.91 | 92.66 | 69.48 | 105.7 | 127.1 | 94.41 | 93.61 | 104.7 | 116.6 | 140.3 | 98.5 | 137.1 | 120 | 165 | 115 |
EBITDA 1 | 12.4 | 19.7 | 4.8 | 14.6 | 24.5 | 10.3 | 35.8 | 10.4 | 16.3 | 24.1 | 23 | 29.98 | - | - | - |
EBIT 1 | 10.05 | 17.7 | 2.147 | 10.04 | 16.99 | 2.219 | 29.87 | 5 | 5.3 | 16.8 | 19.09 | 28.08 | - | - | - |
Operating Margin | 15.03% | 19.1% | 3.09% | 9.5% | 13.37% | 2.35% | 31.91% | 4.78% | 4.55% | 11.97% | 19.38% | 20.48% | - | - | - |
Earnings before Tax (EBT) 1 | - | 9.48 | -2.637 | 2.273 | 8.666 | -7.745 | 22.29 | -4.6 | -2.2 | 9.6 | 13.75 | 22.83 | - | - | - |
Net income 1 | - | 3.427 | -6.487 | -5.147 | 0.4983 | -8.662 | 28.15 | -3.8 | -4.6 | 0.1 | 11.24 | 19.09 | - | - | - |
Net margin | - | 3.7% | -9.34% | -4.87% | 0.39% | -9.18% | 30.07% | -3.63% | -3.95% | 0.07% | 11.41% | 13.92% | - | - | - |
EPS 2 | - | 0.0808 | -0.1577 | -0.1171 | 0.008100 | -0.1381 | 0.4462 | -0.0611 | -0.0732 | 0.001560 | 0.1800 | 0.3000 | 0.0800 | 0.3400 | 0.0800 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 10/11/21 | 10/02/22 | 12/05/22 | 08/09/22 | 10/11/22 | 09/02/23 | 10/05/23 | 11/09/23 | 13/11/23 | 08/02/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | 197 | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | 1.514 x | - |
Free Cash Flow 1 | - | - | -14.5 | -21 | -8.77 | 61.7 | 109 | - |
ROE (net income / shareholders' equity) | - | - | - | - | 7.84% | - | 2.1% | - |
ROA (Net income/ Total Assets) | - | - | - | - | 2.5% | 6.9% | 15.5% | - |
Assets 1 | - | - | - | - | 668.1 | 380.3 | 484.5 | - |
Book Value Per Share 2 | - | - | - | - | 4.590 | 5.720 | 7.990 | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | - | - | 2.81 | 3.46 | 11.4 | 8.5 | 4 | 4 |
Capex / Sales | - | - | 1.34% | 1.03% | 2.71% | 1.73% | 0.67% | 0.51% |
Announcement Date | 13/09/19 | 10/09/20 | 09/09/21 | 08/09/22 | 11/09/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.97% | 811M | |
+19.95% | 40.06B | |
-.--% | 11.1B | |
+7.11% | 8.43B | |
+2.73% | 6.46B | |
-3.19% | 6.09B | |
-6.36% | 5.61B | |
+37.82% | 5.46B | |
-20.49% | 5.11B | |
-11.75% | 4.51B |
- Stock Market
- Equities
- BIOX Stock
- Financials Bioceres Crop Solutions Corp.